Duavee Generic: When Will It Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Duavee Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? TBD no date yet What opens the door is not settled yet
- Has the FDA approved a generic? Not yet None in the FDA’s records yet
- When does the last patent end? March 2027 Its only patent listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
There is no expected month yet for generic bazedoxifene acetate and estrogens, conjugated. None is for sale yet.
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Duavee as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Duavee by the Numbers
- Reason
- Not yet clearNo generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
- How sure
- Not rated Too early to rate.
- Price competition
- None filed yet No filers on record
- Brand sales
- $19M a yearSmaller seller
- FDA approved 2013 October 2013 FDA Orange Book
- Patents listed 1 last runs to March 2027 FDA Orange Book
- Pharmacies pay $6.48 per tablet, up 2.9% in a year NADAC, October 2026
- Medicare Part D spent $1.3M in 2025, for 925 people CMS Part D Spending by Drug
- Medicaid prescriptions 614 in the last four reported quarters, $187K CMS Medicaid drug utilization, to Q1 2026
Duavee’s Road to a Generic
Duavee has had the market to itself since the FDA approved it in October 2013 (Wyeth Pharmaceuticals LLC). Its one listed patent runs to March 2027.
No generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Duavee Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Duavee’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 7,683,051 | The active ingredient; the product’s formulation; a way of using it (U-594, U-904) | March 2027 | Active |
Source: FDA Orange Book, application 022247. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Bazedoxifene Acetate and Estrogens, Conjugated
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Duavee yet.
Approved by the FDA
Not yet. The FDA has not approved a generic bazedoxifene acetate and estrogens, conjugated. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic bazedoxifene acetate and estrogens, conjugated for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Duavee Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Duavee 0.45-20 mg tablet
$6.48 per tablet in October 2026, up 2.9% from a year earlier.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $6.48 |
| September 2026 | $6.48 |
| August 2026 | $6.48 |
| July 2026 | $6.48 |
| June 2026 | $6.48 |
| May 2026 | $6.49 |
| April 2026 | $6.49 |
| March 2026 | $6.49 |
| February 2026 | $6.49 |
| January 2026 | $6.49 |
| February 2024 | $6.30 |
| January 2024 | $6.30 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Duavee today: $6.48 per tablet for Duavee 0.45-20 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Dollar figures apply FDA’s median drops to the $6.48 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Duavee
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Duavee, before manufacturer rebates.
- $329.9K
- January to March 2026, the latest CMS has posted
For 678 people, about $279 per prescription fill - $1.3M
- 2025, the whole year
For 925 people, about $298 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $329,939 | 678 | $279.14 |
| 2025 | $1,333,193 | 925 | $298.12 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Duavee only, so no generic is counted in it. What CMS says it is used for: This combination medication is used by women with a uterus to reduce symptoms of menopause (such as hot flashes, vaginal dryness) and to prevent bone loss (osteoporosis) after menopause. It contains conjugated estrogens and bazedoxifene.
Medicaid Prescriptions by Quarter
614 prescriptions in the four quarters to Q1 2026, $187K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 148 | $49,990 |
| Q4 2025 | 142 | $44,034 |
| Q3 2025 | 157 | $45,152 |
| Q2 2025 | 167 | $47,799 |
| Q1 2025 | 142 | $38,163 |
Source: CMS Medicaid State Drug Utilization Data, over Duavee’s own package codes.
Duavee Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 20MG BASE;0.45MG | Tablet | Oral | October 2013 | Prescription reference product |
Source: FDA Orange Book, Wyeth Pharmaceuticals LLC. Listed for sale today by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. and U.S. Pharmaceuticals (FDA NDC Directory).
Duavee NDC Codes and Packages
Each Duavee package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 00008-1123-12 | ESTROGENS, CONJUGATED .45 mg/1 / BAZEDOXIFENE ACETATE 20 mg/1 tablet, film coated | pouch of 2 blister packs of 15 tablets | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| 00008-1123-12 | ESTROGENS, CONJUGATED .45 mg/1 / BAZEDOXIFENE ACETATE 20 mg/1 tablet, film coated | pouch of 2 blister packs of 15 tablets | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. |
| 63539-0122-07 | ESTROGENS, CONJUGATED .45 mg/1 / BAZEDOXIFENE ACETATE 20 mg/1 tablet, film coated | blister pack of 7 tablets | U.S. Pharmaceuticals |
| 63539-0122-07 | ESTROGENS, CONJUGATED .45 mg/1 / BAZEDOXIFENE ACETATE 20 mg/1 tablet, film coated | blister pack of 7 tablets | U.S. Pharmaceuticals |
Source: the FDA NDC Directory, current listings only. Only packages sold under Duavee’s own FDA approval (NDA 22247) are listed, never a generic. Some codes belong to companies that repackage Duavee: it is the same medicine in a different package.
What a Generic Duavee Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Duavee as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Duavee”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Duavee
Is there a generic for Duavee right now?
No. As of October 9, 2026 no generic bazedoxifene acetate and estrogens, conjugated is listed for sale in the FDA NDC Directory.
When will Duavee go generic?
There is no expected month yet. No generic application is on record yet. The month follows the patents and protections on record, which a challenge or a deal can end early.
Will generic bazedoxifene acetate and estrogens, conjugated be the same as Duavee?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Duavee?
Not yet. The FDA Orange Book lists no approved generic version of Duavee.
When does the Duavee patent expire?
One patent is listed for Duavee in the FDA Orange Book; it runs to March 2027. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (a date that is not known yet) weighs all of that.
How much does Duavee cost now?
Pharmacies paid about $6.48 per tablet for Duavee 0.45-20 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected a date that is not known yet on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- ProcysbiCysteamine BitartrateMarch 2030
- ByqloviClobetasol Propionate2032 to 2033
- TralementCupric Sulfate, Manganese Sulfate, Selenious Acid, and Zinc Sulfate2034 to 2035
- FulvestrantFulvestrantMay 2034
- ZegalogueDasiglucagonMarch 2035
- LumasonSulfur Hexafluoride Lipid-Type A MicrospheresMay 2039
About Duavee
- Generic name bazedoxifene acetate and estrogens, conjugated
- How it is taken By mouth
- Company Wyeth Pharmaceuticals LLC
- More drugs Brand-name drugs starting with D
- Have a question? A pharmacist answers, free. Ask about Duavee
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, FDA NDC Directory, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.